News

27 November 2018 Lysarc
Lymphoma Associated with Breast Implants: LYS...
Not to be missed this evening on France 2 TV, in the program Cash Investiga...
28 June 2018 Calym
The new PRIMA-PI index
A New Simplified and Easy-to-compute Prognostic Scoring System for Routine ...
19 June 2018 Lysa
LYSA’s RELEVANCE Trial in the Media
Return on the presentation of Franck Morschhauser
25 May 2018 Calym
Immunotherapy: a New Bispecific Antibody to T...
Samples from the CeVi collection of the CALYM Carnot Institute were used...
08 January 2018 Lysa
4th LYSA Days, Nantes 2018
The 4th LYSA Days Conference will take place from 8th to 10th of February 2...
21 December 2017 Calym
PRIMA: from the clinical study to translation...
The PRIMA study – Roche collaboration
21 December 2017 Lysarc
French Cooperative Groups in Oncology
Focus on their Contribution to the Fight against Cancer
20 December 2017 Calym
CALYM-IMAGINE Workshop 2018
On 19 January 2018, the CALYM Carnot institute and the IMAGINE Associated C...
19 December 2017 Lysa
Follicular Lymphoma: efficacy of Rituximab ma...
These results from the PRIMA study conducted by LYSA...
15 December 2017 Lysarc
Olivier Hermine nominated at the French Acad...
On 5 December 2017, the plenary assembly of the French Académie des Scienc...
12 October 2017 Calym
Bertrand Nadel, New Manager of the CALYM Carn...
Bertrand Nadel, Inserm research director, head of the “Genomic Instabilit...
27 September 2017 Lysa
Lymphome à cellules du manteau
Une immunothérapie après la chimiothérapie prolonge la survie des patien...
30 May 2017 Calym
Tazemetostat, a New Step in the Development o...
The CALYM Carnot institute and LYSARC are proud to count Epizyme as one of ...